Bryant Furlow

Bryant Furlow is medical journalist working at the crossroads of research, clinical practice, and public policy. His work has appeared The Lancet, New Scientist, and Oncology Nurse Advisor.

Most Recent Articles by Bryant Furlow

Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer

Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer

By

Active surveillance provides an important alternative to immediate treatment for early-stage, low-risk prostate cancers. For men with a relatively short life expectancy, watchful waiting is recommended.

Can the FDA Curb Drug Prices for Cancer Treatment?

Can the FDA Curb Drug Prices for Cancer Treatment?

By

The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.

Industry Payments to Physicians: Confronting Conflicts of Interest

Industry Payments to Physicians: Confronting Conflicts of Interest

By

Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.

Q&A With Roberto Iacovelli, MD: Personalizing Immunotherapy for Renal Cell Carcinoma

Q&A With Roberto Iacovelli, MD: Personalizing Immunotherapy for Renal Cell Carcinoma

By

In this question-and-answer session, Cancer Therapy Advisor asked Dr Iacovelli about his team's recent review regarding the future of personalizing immunotherapy for RCC.

Megakaryocytes and Circulating Tumor Cells: Prognostic Value for Prostate Cancer

Megakaryocytes and Circulating Tumor Cells: Prognostic Value for Prostate Cancer

By

Circulating megakaryocytes are prognostic among patients with prostate cancer, bolstering evidence from breast cancer studies linking megakaryocytes to metastasis.

More Articles by Bryant Furlow

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters